roadmap biopharma begin
three strategi maxim biopharma perform
happi rear-view mirror given volatil uncertainti
surround pandem begin think roadmap
maxim biopharma perform driven three key idea stick qualiti
buy po buy po biomarin
buy po outperform ytd believ could remain
case go earn season expect broad weak embed
earn result think larg number biopharma guid
consid select under-perform name catalyst would
includ bristol-my squibb buy po amgen inc buy po
categori normal market could put stock back
focu exclus specif thesi group gilead scienc
inc neutral po neutral po
neutral po signific outperform ytd
question answer monet therapi especi
upcom phase data hydroxy/chloroquin confer call today
slide start follow page note discuss thought
recent analysi iqvia product demand trend well consensu estim
found show littl chang thu far face global outbreak
dig deeper conduct revenu sensit analysi therapeut
categori requir either high touch invas therapi frequent offic visit
deem less urgent includ retin diseas dermatolog migrain
rare diseas sma assum higher impact sale
indic wherea indic oral therapi
deliv home diabet cardio less impact scenario regeneron
alexion risk much wherea vertex
gilead unaffect think scenario analysi valid stabl iqvia
script data recent week period overal think show resili
mani biopharma brand even worst case scenario patient
skip dose impact manag demand curv like normal
biopharma rel safe overal thought analysi indic
compani may less sensit impact other
initi coverag four new smid-cap
expand smid-cap coverag includ bioxcel buy po
eido neutral po esperion buy po kiniksa buy
po see bioxcel rel de-risk pivot trial readout lead asset
expect eido opportun becom strong
second mover multibillion dollar market treat fatal form cardiomyopathi
although key data still way away esperion gear first product launch
view lead investor revisit name sooner smid-
cap lastli kiniksa broad in-licens pipelin alreadi demonstr
aspect clinic valid also highlight recent initi coverag
neoleukin nltx buy po biopharma sector detail well initi
provid subsequ page initi report link
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
industri analysi expand coverag
provid slide detail updat view biopharma sector new
coverag launch bioxcel buy po eido neutral po
esperion buy po kiniksa buy po neoleukin nltx buy
exhibit set biopharma go
exhibit rel industri segment healthcar pharma remain defens ytd
exhibit chronic med gener essenti higher touch deliveri mean higher risk disrupt
exhibit corpor commentari larg affirm view
exhibit biopharma sensit select volum disrupt
exhibit group biopharma segment base similar profil
exhibit also segment biopharma variou investor scenario find relev research
bioxcel rapidli move de-risk lead asset clinic
potenti continu add addit indic acut agit time
see high risk high reward asset current given littl
rate neutral believ market opportun attract
believ sale opportun larg factor level await
detail phase data addit insight
esperion lead product nexletol bempedo acid ba oral altern ldl-c
lower oral dose potenti combin zetia could attract specialist
pcp remain cautiou long-term outlook see upsid
current price on-going launch
view kiniksa offer compel long-term opportun investor given
diversifi pipelin led experienc manag team kiniksa advanc
pipelin mani candid alreadi demonstr clinic valid
contrast mani clinic stage peer look continu progress de-risk
portfolio provid meaning upsid share kiniksa continu
evolut commercialize-stag biopharma
po per share valu use sum part npv
analysi market pipelin drug assum rang
weight averag cost capit wacc approv drug
pipelin drug base stage approv product market life pipelin
develop termin growth rate new launch legaci
product po also reflect net cash
upsid risk price object slower expect eros neulasta
esa franchis faster growth aimovig repatha even prolia
better expect clinic trial result oncolog pipelin
downsid risk price object faster expect revenu eros
legaci brand slower expect growth new drug launch clinic trial
valuat approach share employ discount cash flow analysi
approv pipelin product reflect price object valu biomarin
share use sum part npv analysi approv pipelin drug
assum weight averag cost capit wacc biomarin drug
gener earli launch pipelin develop termin growth rate
assumpt npv analysi suggest market product valu
pipelin product valu cash valu
risk price object faster expect revenu runoff kuvan
competit orphan drug develop slower expect growth new
drug launch clinic trial failur
po base sum-of part valuat assum discount rate
program likelihood success po
schizophrenia phase bipolar disord phase indic
dementia phase opioid withdraw ind indic given well
document safeti efficaci iv dexmedetomidin ascrib higher po
would typic ascrib indic given current ascrib
asset asset royalti cash
downsid risk failur phase trial limit commerci uptak limit
formulari access due price
price object po base blend averag risk-adjust
discount cash flow dcf price-to-earnings multipl appli ep dcf assum
wacc termin growth rate assum approxim
price-to-earnings multipl given impend patent cliff risk associ later-stag
pipelin asset pend celgen acquisit
risk po uninspir readout late-stag trial key i/o indic
nsclc rcc rapid deceler revlimid eros expect
neg outcom compani later-stag pipelin asset develop
pressur headlin risk face sector includ drug price reform
risk associ close propos celgen acquisit
price object po base sum-of-the-part analysi po includ
attr-cm attr-pn form cash use
wacc zero termin valu
downsid risk po neg phase result posit clinic data
compet therapi unexpect safeti signal clinic trial slow diagnosi
attr-cm patient
upsid risk po neg clinic data compet therapi data
suggest potent stabil lead better outcom fast diagnosi
attr-cm patient increas market opportun
compani
price object base probability-adjust net present valu npv
analysi franchis vertic includ endocrinolog oncolog
pharmaceut product earli pipelin asset well
approxim net cash use wacc rang approv
product pipelin product depend stage develop appli
termin valu rang cardiolog pipelin base project sale
declin follow loss exclus within busi vertic
risk price object better expect launch compet
product emerg clinic data pipelin asset confirm prior
observ failur effect commerci approv product potenti
drug price system restructur us
dcf-deriv po base bempedo acid franchis
net cash assum discount rate bempedo acid given risk
associ one-product franchis model extend model
downsid risk price object failur bempedo acid cvot
unexpect safeti signal post-launch greater competit therapi
wors expect initi launch trend price pressur competitor
upsid risk price object addit partnership deal upsid
launch expect near long term strong cvot data ahead
price object base sum-of-th part npv analysi forecast sale
key franchis product use wacc includ termin valu
appropri assumpt valu hiv franchis hcv
kite platform filgotinib pipelin
net cash
upsid risk stronger expect sale biktarvi hiv less eros
genvoya/ odefsey sale faster uptak descovi prep greater durabl
hcv revenu rapid uptak yescarta filgotinib success nash trial
pipelin may lead investor assign valu program
downsid risk moder sale biktarvi genvoya odefsey due
competit may long-act inject greater expect
eros hcv revenu limit upsid gilead car-t filgotinib launch
may meaning delay market penetr product class
slow safeti concern
use sum part npv model valu kiniksa share base risk adjust
revenu forecast estim margin assumpt price object base
sum-of-th part npv analysi forecast sale key product rilonacept
mavrilimumab use wacc termin valu
assumpt valu rilonacept mavrilimumab earli pipelin
sh net cash
upsid risk po includ stronger expect phase phase poc data
upsid rilonacept mavrilimumab launch expect rapid progress
develop
po base probability-adjust npv five differ part includ
oncolog cardiovascular diseas rare diseas
net cash estim sale pipelin program slate move
forward probabl success rang use wacc
core program exploratori program termin growth rate
risk po delay pipelin develop unexpect safeti find
delay product approv disappoint launch greater expect
competit financi risk due larg cash burn potenti upsid
npv sum-of-the-part valuat give price object nltx
includ net cash technolog platform
assum wacc termin growth rate
upsid risk faster-than-expect launch ev tucatinib well increas
uptak adcetri hl success trial pipelin could lead investor begin
assign valu program
downsid risk clinic trial failur unexpect safeti issu emerg
compet product superior profil disappoint uptak new product launch
could result lower cash flow
price object base probability-adjust net present valu npv
analysi eylea includ ou revenu bayer collabor
sanofi collabor revenu includ dupix product revenu
libtayo earli pipelin asset well
approxim net cash use wacc rang approv
product pipelin product termin growth eylea earli
downsid risk price object slower-than-expect growth product
sale particularli eylea dupix failur obtain approv addit
indic dupix pipelin setback
upsid risk price object better expect eylea growth trajectori
larger contribut dupix regeneron top-line commerci uptak
new indic better expect econom realiz regeneron
price object vertex base npv analysi
forecast sale approv product kalydeco orkambi symdeko
trikafta assum wacc line peer compani
similar size risk vari termin growth rate asset base
characterist patent life given assumpt estim
valu kalydeco orkambi symdeko
trikafta net cash pipelin
risk price object payer pushback price difficulti secur
reimburs agreement particularli eu clinic trial failur new
competitor cystic fibrosi
geoff meacham greg harrison cfa herebi certifi view us
express research report accur reflect respect person
view subject secur issuer also certifi part
respect compens directli indirectli relat specif
recommend view express research report
